BloodScan Completes Its First International Installation of Labyrinth One, in South Korea

BloodScan Biotech completed its first international installation of Labyrinth One in South Korea in late September 2026, including two days of on-site installation and operator training.

The customer will use Labyrinth One to isolate intact, label-free live cells from clinical samples as the front end of its single-cell sequencing research.

We will continue to provide technical support as the customer integrates the system into its research workflow.